Tag
cancer
2 articles
Lilly Spends $1.5B on Calytrix Bio as M&A Pace Hits $32B in 2026
Eli Lilly's acquisition of the immunology-focused biotech adds to a record year of deal-making as the pharma giant prioritizes external growth in oncology.

Moderna at $225: Melanoma Data and NIH Backing Justify Bull Case
Moderna has surged 600 percent in 2026 on melanoma vaccine efficacy and reported NIH support for personalized cancer vaccines, with analysts modeling $225 as fair value.